Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among ChronicKidneyDisease Patients: A Systematic Review and Meta-Analysis Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among ChronicKidneyDisease Patients: A Systematic Review and Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square (...) does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Improvements in Fatigue at Higher Achieved Hemoglobin Levels Among ChronicKidneyDisease Patients: A Systematic Review and Meta-Analysis Murilo Guedes, Camila R. Guetter, Lucas HO Erbano, Andre G. Palone, Jarcy Zee, Bruce M. Robinson
Disease Guideline, July 2019 Clinical Problem and Management Issues Chronickidneydisease (CKD) is an increasingly common clinical problem that raises a patient’s risk for developing several life-threatening medical conditions, including end- stage renaldisease (ESRD) and cardiovascular disease (CVD). Appropriate treatment can delay or prevent these adverse outcomes. However, CKD is often not recognized by clinicians or patients and as a result is often not optimally treated. Prevalence (...) indicating presence of abnormal kidney structure or function for 3 or more months can establish the diagnosis of CKD (Table 1). Ruling out acute (or acute on chronic) kidney injury involves clinical 13 UMHS ChronicKidneyDisease Guideline, July 2019 judgment in the clinical context of either estimated GFR (eGFR) 20% in eGFR, or an increase in serum creatinine = 0.3. During the initial evaluation of CKD, common causes and predisposing conditions for acutely decreased eGFR, including pre-renal and post
). Evaluating the prevalence and opportunity for technology use in chronickidneydisease patients: A cross-sectional study. BMC Nephrology, 19(1), 4–11. https://doi.org/10.1186/s12882-018-0830-8 Chiou, C. P., & Chung, Y. C. (2012). Effectiveness of multimedia interactive patient education on knowledge, uncertainty and decision-making in patients with end-stage renaldisease. Journal of Clinical Nursing, 21(9–10), 1223–1231. https://doi.org/10.1111/j.1365-2702.2011.03793.x Cicolini, G., Simonetti, V (...) ., & Chang, P. (2014). Mockup design of personal health diary app for patients with chronickidneydisease. Studies in Health Technology and Informatics, 201, 124–132. https://doi.org/10.3233/978-1-61499-415-2-124 McGillicuddy, J. W., Gregoski, M. J., Weiland, A. K., Rock, R. A., Brunner-Jackson, B. M., Patel, S. K., … Treiber, F. A. (2013). Mobile Health Medication Adherence and Blood Pressure Control in Renal Transplant Recipients: A Proof-of-Concept Randomized Controlled Trial. JMIR Research Protocols
publication KDIGO 2012 Clinical practice guideline for the evaluation and management of chronickidneydisease [ ], and expert opinion in review articles on CKD [ ; ; ; ]. Investigating people with risk factors for CKD The aim of early identification and treatment of CKD is to decrease the risk of cardiovascular disease, progression to end-stage renaldisease (ESRD), and mortality. The recommendation to investigate people with risk factors for CKD is based on the NICE clinical guideline [ ] and expert (...) Chronickidneydisease: When should I suspect chronickidneydisease? Diagnosis | Diagnosis | Chronickidneydisease | CKS | NICE Search CKS… Menu Diagnosis Chronickidneydisease: When should I suspect chronickidneydisease? Last revised in May 2020 When should I suspect chronickidneydisease? Arrange to assess for chronickidneydisease (CKD) in people with: for CKD. An incidental finding of: Raised serum creatinine and/or a serum estimated glomerular filtration rate (eGFR) of less than 60
. Note: a significant reduction in serum creatinine, for example by more than 20%, may indicate significant renal impairment, in the presence of normal eGFR readings. Based on: [ ; ] Basis for recommendation The recommendations on initial investigations are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines Chronickidneydisease. Early identification and management of chronickidneydisease in adults in primary and secondary care [ ] and Suspected cancer (...) Chronickidneydisease: What initial investigations should I arrange? Initial investigations | Diagnosis | Chronickidneydisease | CKS | NICE Search CKS… Menu Initial investigations Chronickidneydisease: What initial investigations should I arrange? Last revised in May 2020 What initial investigations should I arrange? If a diagnosis of chronickidneydisease (CKD) is , arrange initial investigations in primary care. Arrange blood tests for serum creatinine and estimated glomerular
Chronickidneydisease: Scenario: COVID-19 Scenario: COVID-19 | Management | Chronickidneydisease | CKS | NICE Search CKS… Menu Scenario: COVID-19 Chronickidneydisease: Scenario: COVID-19 Last revised in May 2020 Scenario: COVID-19 From age 18 years onwards. How should my management vary when considering the possibility of COVID-19? In people with chronickidneydisease (CKD) and in the presence of the COVID-19 pandemic, National Institute of Health and Care Excellence (NICE) has made (...) when they should seek help and who to contact. Referrals to renal services To minimize risk from COVID‑19, NICE advises that clinicians should delay referral if the clinical need is not urgent, for example, if the person has mild-to-moderate proteinuria and a stable eGFR (including people with suspected inherited kidneydisease). Continue to refer people for urgent outpatient appointments if there is a clinical need, for example, if the person has accelerated progression of CKD, which is defined
Chronickidneydisease: How should I assess suspected chronickidneydisease? Assessment | Diagnosis | Chronickidneydisease | CKS | NICE Search CKS… Menu Assessment Chronickidneydisease: How should I assess suspected chronickidneydisease? Last revised in May 2020 How should I assess suspected chronickidneydisease? If a diagnosis of chronickidneydisease (CKD) is , assess the person for possible associated clinical features. Ask about: General symptoms, such as lethargy, itch (...) , breathlessness, cramps (often worse at night), sleep disturbance, bone pain, or loss of appetite, vomiting, weight loss, and taste disturbance (often present with end-stage disease). Urine output, such as polyuria (tubular concentrating ability is impaired); oliguria; nocturia (due to impaired solute diuresis or oedema); or anuria (due to possible acute kidney injury [AKI], obstructive uropathy causing urinary retention; or end-stage renaldisease). Any potentially , including over-the-counter or herbal
Chronickidneydisease: ACE-inhibitors and AIIRAs ACE-inhibitors and AIIRAs | Prescribing information | Chronickidneydisease | CKS | NICE Search CKS… Menu ACE-inhibitors and AIIRAs Chronickidneydisease: ACE-inhibitors and AIIRAs Last revised in May 2020 ACE-inhibitors and AIIRAs Contraindications and cautions Use of angiotensin-converting enzyme (ACE) inhibitors is contraindicated in people: With a history of angio-oedema associated with previous exposure to an ACE-inhibitor (...) -dose diuretics may result in volume depletion and a risk of hypotension. Lithium — reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration. Monitoring of serum lithium levels is recommended. NSAIDs — attenuation of antihypertensive effect may occur and there may be an increased risk of deteriorating renal function, including possible acute kidney injury and hyperkalaemia. Consider monitoring renal function after starting concomitant
anaemia, renal mineral and bone disorder, end-stage renaldisease (ESRD), and increased all-cause mortality. CKD should be suspected in people with: Risk factors for CKD. An incidental finding of raised serum creatinine and/or eGFR of less than 60 mL/min/1.73 m 2 ; or markers of kidney damage. Possible clinical features of CKD (rare unless end-stage disease). If a diagnosis of CKD is suspected, initial investigations should be arranged and repeated as appropriate: Serum creatinine and eGFR. Early (...) ChronickidneydiseaseChronickidneydisease | Topics A to Z | CKS | NICE Search CKS… Menu ChronickidneydiseaseChronickidneydisease Last revised in May 2020 Chronickidneydisease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health Diagnosis Management Prescribing information Background information Chronickidneydisease: Summary Chronickidneydisease (CKD) is a reduction in kidney function or structural damage
, and treatment of chronickidneydisease-mineral and bone disorder (CKD-MBD) [ ]; and expert opinion in review articles on chronickidneydisease (CKD) [ ; ; ; ]. Monitoring estimated glomerular filtration rate (eGFR) and urinary albumin:creatinine ratio (ACR) to identify disease progression Early detection of disease progression can allow for timely preparation for renal replacement therapy, if indicated, for people with CKD stage 4 before progression to stage 5 disease [ ]. People with a declining (...) , phosphate, calorie and salt intake; and end-stage renaldisease (ESRD) may require renal replacement therapy (haemodialysis/peritoneal dialysis or eventual kidney transplantation). Renal anaemia may include treatment with erythropoiesis-stimulating agents, and possible intravenous iron if there is associated refractory iron deficiency. Renal mineral and bone disorder may involve phosphate dietary restriction, use of phosphate binders, and specialist endocrinology input. Persistent metabolic acidosis may
information view the page. Please read and accept the and check the box to generate a sharing link. I have read and accept the terms and conditions Share URL copied to clipboard View permissions information for this article The Association Between ChronicKidneyDisease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis .entryAuthor" data-author-container-selector=".NLM_contrib-group"> Show all authors 1 Faculty of Medicine, Universitas Pelita Harapan, Tangerang (...) ). Abbreviations: ARDS: acute respiratory distress syndrome; CKD: chronickidneydisease; COVID-19: Coronavirus Disease 2019; IC: intensive care. Renal replacement therapy and poor outcome in COVID-19 The new onset RRT was associated with increased composite poor outcome (RR 18.04 [4.44, 73.25], P < .001; I 2 : 87%, P < .001). Subgroup analysis also showed significantly increased risk for mortality (RR 26.02 [5.01, 135.13], P < .001; I 2 : 60%, P = .06), severe COVID-19 (RR 12.95 [1.93, 86.82], P = .008; I 2
in patients with chronickidneydisease (CKD), and these patients have a 10–30 times higher cardiovascular mortality risk than the general population [ ]. In addition to the classic tetrad of smoking, diabetes, dyslipidaemia, and hypertension, mineral and bone metabolism disorders are also identified as risk factors for cardiovascular mortality in patients with CKD [ - ]. Osteoprotegerin (OPG) is a secretory glycoprotein of the TNF receptor superfamily [ ] and has been reported to be involved in bone (...) the literature search. Q.H., J.L., and F.H. selected the included studies. N.H. and X.H. extracted data from each included study. F.H. and Y.L. assessed the study quality. Q.H. prepared the tables and all figures. F.H. supervised the study and acted as an arbitrator for all possible disagreements. All authors read and approved the content. Related Articles: References Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronicrenaldisease. Am J Kidney Dis. 1998 Nov;32(5
mellitus and concomitant chronickidneydisease. Med J Chin PLA. 2014;39(1): 546-552 Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D’Ambrosio A, et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty–contrast-induced nephropathy] trial. Am J Cardiol. 2011;108(1):1–7 Quintavalle C (...) , Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012;126(25):3008–16. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F. Usefulness of Atorvastatin (80 mg) in Prevention of Contrast-Induced Nephropathy in Patients With ChronicRenalDisease. The American Journal of Cardiology. 20013;105(3):288-292. Abaci O, Arat Ozkan A, Kocas C, Cetinkal G
Association of Baclofen With Encephalopathy in Patients With ChronicKidneyDisease. At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronickidneydisease (CKD).To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers.Retrospective
Development of Risk Prediction Equations for Incident ChronicKidneyDisease. Early identification of individuals at elevated risk of developing chronickidneydisease (CKD) could improve clinical care through enhanced surveillance and better management of underlying health conditions.To develop assessment tools to identify individuals at increased risk of CKD, defined by reduced estimated glomerular filtration rate (eGFR).Individual-level data analysis of 34 multinational cohorts from the CKD (...) %) had a slope of observed to predicted risk between 0.80 and 1.25. Discrimination was similar in 18 study populations in 9 external validation cohorts; calibration showed that 16 of 18 (89%) had a slope of observed to predicted risk between 0.80 and 1.25.Equations for predicting risk of incident chronickidneydisease developed from more than 5 million individuals from 34 multinational cohorts demonstrated high discrimination and variable calibration in diverse populations. Further study is needed
Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of ChronicKidneyDisease and Potential Transplant. This article discusses potential indications for genetic testing in an African American patient with chronickidneydisease who is being evaluated for a kidney transplant. Two known risk variants in the APOL1 (apolipoprotein L1) gene predispose to kidneydisease and are found almost exclusively in persons of African ancestry. APOL1 risk variants are considered, including (...) whether clinicians should incorporate genetic testing in the screening process for living kidney donors. In addition to APOL1 testing, the role of diagnostic exome sequencing in evaluating potential transplant recipients and donors with a positive family history of kidneydisease is discussed.
ChronicKidneyDisease Diagnosis and Management: A Review. Chronickidneydisease (CKD) is the 16th leading cause of years of life lost worldwide. Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidneydisease, and death.Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg (...) per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide. In developed countries, CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. Optimal management of CKD includes cardiovascular risk
Dietary Priority Screening for ChronicKidneyDisease: Clinical Effectiveness and Guidelines Dietary Priority Screening for ChronicKidneyDisease: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Dietary Priority Screening for ChronicKidneyDisease: Clinical Effectiveness and Guidelines Dietary Priority Screening for ChronicKidneyDisease: Clinical Effectiveness and Guidelines Last updated: January 14, 2019 Project Number: RB1297-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of dietary/nutrition priority screening tools for in-patients and outpatients with chronickidneydisease? What are the evidence-based guidelines for the use of dietary/nutrition prioritization tools for the delivery of nutritional therapy in the chronickidneydisease setting? Key Message One non-randomized study and three evidence based guidelines were identified regarding the use